wp1066
Small moleculeexperimental
Clinical trial activity
3 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2017 (NCT01904123)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase JAK2INHIBITOR
JAK2 inhibitor
STAT3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- wp1066
- wp1066
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05879250 | Phase 2 | Dec 27, 2024 | Moleculin, LLC, National Cancer Institute (NCI), Northwestern University |
| NCT04334863 | Phase 1 | Apr 30, 2020 | CURE Childhood Cancer, Inc., Emory University |
| NCT01904123 | Phase 1 | Jun 1, 2017 | National Cancer Institute (NCI), National Institutes of Health (NIH), University of Texas at Houston |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2017 |
| CURE Childhood Cancer, Inc. | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Moleculin, LLC | For profit | 1 | 0 | 1 | 2024 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2017 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2017 |
7 organizations
Page 1 / 1